Leave a request
The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol) when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.
The under-the-skin injection is the first to be approved since 2014 for the chronic weight management of adults with general obesity or overweight. Indications for this drug are chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater.
Wegovy targets brain areas that control appetite by mimicking a hormone called glucagon-like peptide-1 (GLP-1). A gradual increase of 2.4 mg once weekly must be made over 16 to 20 weeks to reduce gastrointestinal side effects.
Four 68-week trials have been conducted to evaluate Wegovy's efficacy and safety. Participants without diabetes constituted the largest placebo-controlled trial. The average age of the patients at the start of the study was 46 years, and 74% of them were female. According to the results of this study, individuals who took Wegovy lost 6.2% of their starting body weight.
Patients with severe allergies to semaglutide or any other component of Wegovy should not use this medication.
Based on: NewsMedical
#News #Health #Medical #Wegovy #FDA #Whealthnews
Leave a request